USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy

Wenjun Xiong,Xueliang Gao,Tiantian Zhang,Baishan Jiang,Ming-Ming Hu,Xia Bu,Yang Gao,Lin-Zhou Zhang,Bo-Lin Xiao,Chuan He,Yishuang Sun,Haiou Li,Jie Shi,Xiangling Xiao,Bolin Xiang,Conghua Xie,Gang Chen,Haojian Zhang,Wenyi Wei,Gordon J. Freeman,Hong-Bing Shu,Haizhen Wang,Jinfang Zhang

DOI: https://doi.org/10.1038/s41467-022-29401-6

IF: 16.6

2022-03-31

Nature Communications

Abstract:Abstract Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15–25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME). Mechanistically, USP8 inhibition increases PD-L1 protein abundance through elevating the TRAF6-mediated K63-linked ubiquitination of PD-L1 to antagonize K48-linked ubiquitination and degradation of PD-L1. In addition, USP8 inhibition also triggers innate immune response and MHC-I expression largely through activating the NF-κB signaling. Based on these mechanisms, USP8 inhibitor combination with PD-1/PD-L1 blockade significantly activates the infiltrated CD8 + T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. Thus, our study reveals a potential combined therapeutic strategy to utilize a USP8 inhibitor and PD-1/PD-L1 blockade for enhancing anti-tumor efficacy.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper aims to address the following issues: 1. **Understanding the mechanisms behind the low response rate of PD-1/PD-L1 immunotherapy**: Although immunotherapy targeting the PD-1/PD-L1 pathway has achieved significant efficacy in the treatment of various cancers, its moderate response rate (15%-25%) and the resistance mechanisms to PD-1/PD-L1 blockade have not been fully elucidated. 2. **Exploring the potential efficacy of combining USP8 inhibitors with PD-1/PD-L1 blockade**: By studying the mechanism of action of USP8 (a deubiquitinating enzyme), the paper reveals how it reshapes the inflammatory tumor microenvironment (TME) to enhance the effectiveness of anti-PD-1/PD-L1 immunotherapy. Specifically, the paper finds that USP8 inhibition can significantly increase PD-L1 protein levels by counteracting K48-linked ubiquitination and degradation through enhancing TRAF6-mediated K63-linked ubiquitination. Additionally, USP8 inhibition triggers innate immune responses and MHC-I expression, primarily through the activation of the NF-κB signaling pathway. These mechanisms suggest that the combination of USP8 inhibitors with PD-1/PD-L1 blockade can significantly activate infiltrating CD8+ T cells, inhibit tumor growth, and improve survival benefits in mouse tumor models. Therefore, this study reveals a potential combination therapy strategy that utilizes USP8 inhibitors with PD-1/PD-L1 blockade to enhance anti-tumor effects.

USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy

Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer

USP8 Deubiquitinates PD-L1 to Suppress the Immunotherapy of Pancreatic Ductal Carcinoma

USP8 promotes cancer progression and extracellular vesicle‐mediated CD8+ T cell exhaustion by deubiquitinating the TGF‐β receptor TβRII

Inhibition of USP1 Reverses the Chemotherapy Resistance Through Destabilization of MAX in the Relapsed/refractory B-cell Lymphoma

ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

USP18 Is Associated with PD-L1 Antitumor Immunity and Improved Prognosis in Colorectal Cancer

USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer

USP51/PD‐L1/ITGB1‐deployed juxtacrine interaction plays a cell‐intrinsic role in promoting chemoresistant phenotypes in non‐small cell lung cancer

Targeting the TRIM14/USP14 Axis Enhances Immunotherapy Efficacy by Inducing Autophagic Degradation of PD-L1

USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers

EZH2 Inhibition Enhances PD‐L1 Protein Stability Through USP22‐Mediated Deubiquitination in Colorectal Cancer

Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

DPP Inhibition Enhances the Efficacy of PD-1 Blockade by Remodeling the Tumor Microenvironment in Lewis Lung Carcinoma Model

Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs

Deubiquitination and Stabilization of PD-L1 by USP21

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants

Unlocking PD‐1 antibody resistance: The MUC1 DNA vaccine augments CD8+ T cell infiltration and attenuates tumour suppression